BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: D’silva KM, Serling-boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM, Choi HK, Sparks JA, Wallace ZS. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’. Ann Rheum Dis 2020;79:1156-62. [DOI: 10.1136/annrheumdis-2020-217888] [Cited by in Crossref: 86] [Cited by in F6Publishing: 89] [Article Influence: 43.0] [Reference Citation Analysis]
Number Citing Articles
1 Lauper K, Bijlsma JWJ, Burmester GR. Trajectories of COVID-19 information in the Annals of the Rheumatic Diseases: the first months of the pandemic. Ann Rheum Dis 2021;80:26-30. [PMID: 33055081 DOI: 10.1136/annrheumdis-2020-219217] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Raihan M, Hassan MM, Hasan T, Bulbul AA, Hasan MK, Hossain MS, Roy DS, Awal MA. Development of a Smartphone-Based Expert System for COVID-19 Risk Prediction at Early Stage. Bioengineering 2022;9:281. [DOI: 10.3390/bioengineering9070281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhu Y, Zhong J, Dong L. Epidemiology and Clinical Management of Rheumatic Autoimmune Diseases in the COVID-19 Pandemic: A Review. Front Med (Lausanne) 2021;8:725226. [PMID: 34490312 DOI: 10.3389/fmed.2021.725226] [Reference Citation Analysis]
4 Li X, Tong X, Yeung WWY, Kuan P, Yum SHH, Chui CSL, Lai FTT, Wan EYF, Wong CKH, Chan EWY, Lau CS, Wong ICK. Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong. Ann Rheum Dis 2021:annrheumdis-2021-221571. [PMID: 34686479 DOI: 10.1136/annrheumdis-2021-221571] [Reference Citation Analysis]
5 Stradner MH, Dejaco C, Zwerina J, Fritsch-Stork RD. Rheumatic Musculoskeletal Diseases and COVID-19 A Review of the First 6 Months of the Pandemic. Front Med (Lausanne) 2020;7:562142. [PMID: 33154972 DOI: 10.3389/fmed.2020.562142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
6 Fitzgerald GE, Maguire S, Haroon N. COVID-19: What Do Rheumatologists Need to Know? Curr Rheumatol Rep. 2021;23:5. [PMID: 33403528 DOI: 10.1007/s11926-020-00971-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Tam LS, Tanaka Y, Handa R, Li Z, Lorenzo JP, Louthrenoo W, Hill C, Pile K, Robinson PC, Dans LF, Hsu LY, Lee SM, Cho J, Hasan ATMT, Salim B, Samreen S, Shaharir SS, Wong P, Chau J, Danda D, Haq SA. Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic. Int J Rheum Dis 2021;24:733-45. [PMID: 33945214 DOI: 10.1111/1756-185X.14124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 de Oliveira SM, Martins LVDO, Lupino-assad AP, Medeiros-ribeiro AC, de Moraes DA, Del-rio APT, Oliveira MC, Sampaio-barros PD, Kayser C. Severity and mortality of COVID-19 in patients with systemic sclerosis: a Brazilian multicenter study. Seminars in Arthritis and Rheumatism 2022. [DOI: 10.1016/j.semarthrit.2022.151987] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Paik JJ, Sparks JA, Kim AH. Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases. Current Opinion in Pharmacology 2022. [DOI: 10.1016/j.coph.2022.102243] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Haslak F, Varol SE, Gunalp A, Kaynar O, Yildiz M, Adrovic A, Sahin S, Kes G, Ayzit-kilinc A, Akdeniz B, Onal P, Apaydin G, Aygun D, Arslan H, Kilic-baskan A, Hepkaya E, Meral O, Barut K, Cokugras HC, Kasapcopur O. Comparisons of Clinical Features and Outcomes of COVID-19 between Patients with Pediatric Onset Inflammatory Rheumatic Diseases and Healthy Children. JCM 2022;11:2102. [DOI: 10.3390/jcm11082102] [Reference Citation Analysis]
11 García-Maturano JS, Torres-Ordaz DE, Mosqueda-Gutiérrez M, Gómez-Ruiz C, Vázquez-Mellado A, Tafoya-Amado A, Peláez-Ballestas I, Burgos-Vargas R, Vázquez-Mellado J. Gout during the SARS-CoV-2 pandemic: increased flares, urate levels and functional improvement. Clin Rheumatol 2021. [PMID: 34822044 DOI: 10.1007/s10067-021-05994-z] [Reference Citation Analysis]
12 Romão VC, Cordeiro I, Macieira C, Oliveira-Ramos F, Romeu JC, Rosa CM, Saavedra MJ, Saraiva F, Vieira-Sousa E, Fonseca JE. Rheumatology practice amidst the COVID-19 pandemic: a pragmatic view. RMD Open 2020;6:e001314. [PMID: 32584782 DOI: 10.1136/rmdopen-2020-001314] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
13 Brito-Zerón P, Melchor S, Seror R, Priori R, Solans R, Kostov B, Baldini C, Carubbi F, Callejas JL, Guisado-Vasco P, Hernández-Molina G, Pasoto SG, Valim V, Sisó-Almirall A, Mariette X, Carreira P, Ramos-Casals M; Sjögren Big Data Consortium, Members of the EULAR-SS Task Force Big Data Consortium who contributed to this study. SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients. Rheumatology (Oxford) 2021;60:2946-57. [PMID: 33316070 DOI: 10.1093/rheumatology/keaa748] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
14 Mena-Vázquez N, Manrique Arija S, Rojas-Giménez M, Raya-Álvarez E, Velloso-Feijoó ML, López-Medina C, Ramos-Giraldez C, Godoy-Navarrete FJ, Redondo-Rodríguez R, Cabezas-Lucena AM, Morales-Águila M, Romero-Barco CM, Fernández-Nebro A. Hospitalization and mortality from COVID-19 of patients with rheumatic inflammatory diseases in Andalusia. Reumatol Clin (Engl Ed) 2021:S2173-5743(21)00162-3. [PMID: 34538612 DOI: 10.1016/j.reumae.2021.02.006] [Reference Citation Analysis]
15 Wang Q, Liu J, Shao R, Han X, Su C, Lu W. Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis. Rheumatol Int 2021;41:851-61. [PMID: 33687528 DOI: 10.1007/s00296-021-04803-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
16 Kridin K, Schmidt E. Epidemiology of Pemphigus. JID Innovations 2021;1:100004. [DOI: 10.1016/j.xjidi.2021.100004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Rocha APD, Atallah ÁN, Pinto ACPN, Rocha-Filho CR, Milby KM, Civile VT, Carvas Junior N, Reis FSA, Ferla LJ, Ramalho GS, Trevisani GFM, Puga MEDS, Trevisani VFM. COVID-19 and patients with immune-mediated inflammatory diseases undergoing pharmacological treatments: a rapid living systematic review. Sao Paulo Med J 2020;138:515-20. [PMID: 33331606 DOI: 10.1590/1516-3180.2020.0421.R2.10092020] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Nuñez DF, Leon L, Garcia AM, Arce JIC, Mucientes A, Gutierrez-fernandez B, Rodriguez L, Cristóbal IPS, Álvarez P, Prada CM, Abasolo L. Mortality related to COVID-19 in patients with rheumatic and musculoskeletal diseases, first wave of the outbreak: a single-center study. Therapeutic Advances in Musculoskeletal 2022;14:1759720X2210902. [DOI: 10.1177/1759720x221090296] [Reference Citation Analysis]
19 Hausmann JS, Kennedy K, Simard JF, Liew JW, Sparks JA, Moni TT, Harrison C, Larché MJ, Levine M, Sattui SE, Semalulu T, Foster G, Surangiwala S, Thabane L, Beesley RP, Durrant KL, Mateus EF, Mingolla S, Nudel M, Palmerlee CA, Richards DP, Liew DFL, Hill CL, Bhana S, Costello W, Grainger R, Machado PM, Robinson PC, Sufka P, Wallace ZS, Yazdany J, Sirotich E; COVID-19 Global Rheumatology Alliance. Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. Lancet Rheumatol 2021. [PMID: 34316727 DOI: 10.1016/S2665-9913(21)00175-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Kridin K, Schonmann Y, Damiani G, Peretz A, Onn E, Bitan DT, Cohen AD. Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis-A population-based cohort study. Dermatol Ther 2021;34:e15003. [PMID: 34033207 DOI: 10.1111/dth.15003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Fung M, Babik JM. COVID-19 in Immunocompromised Hosts: What We Know So Far. Clin Infect Dis. 2021;72:340-350. [PMID: 33501974 DOI: 10.1093/cid/ciaa863] [Cited by in Crossref: 95] [Cited by in F6Publishing: 99] [Article Influence: 95.0] [Reference Citation Analysis]
22 Kridin K, Schonmann Y, Tzur Bitan D, Damiani G, Peretz A, Weinstein O, Cohen AD. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization and Mortality in Patients with Psoriasis: A Population-Based Study. Am J Clin Dermatol 2021;22:709-18. [PMID: 34060006 DOI: 10.1007/s40257-021-00605-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
23 Faye AS, Lee KE, Laszkowska M, Kim J, Blackett JW, McKenney AS, Krigel A, Giles JT, Wang R, Bernstein EJ, Green PHR, Krishnareddy S, Hur C, Lebwohl B. Risk of Adverse Outcomes in Hospitalized Patients With Autoimmune Disease and COVID-19: A Matched Cohort Study From New York City. J Rheumatol 2021;48:454-62. [PMID: 33132221 DOI: 10.3899/jrheum.200989] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
24 Bakasis AD, Mavragani CP, Boki KA, Tzioufas AG, Vlachoyiannopoulos PG, Stergiou IE, Skopouli FN, Moutsopoulos HM. COVID-19 infection among autoimmune rheumatic disease patients: Data from an observational study and literature review. J Autoimmun 2021;123:102687. [PMID: 34311142 DOI: 10.1016/j.jaut.2021.102687] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Schulze-Koops H, Iking-Konert C, Leipe J, Hoyer BF, Holle J, Moosig F, Aries P, Burmester G, Fiehn C, Krause A, Lorenz HM, Schneider M, Sewerin P, Voormann A, Wagner U, Krüger K, Specker C; Kommission Pharmakotherapie., Vorstand der Deutschen Gesellschaft für Rheumatologie. [Recommendations of the German Society for Rheumatology for management of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic - Update July 2020]. Z Rheumatol 2020;79:679-85. [PMID: 32757030 DOI: 10.1007/s00393-020-00851-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
26 Haberman RH, Castillo R, Chen A, Yan D, Ramirez D, Sekar V, Lesser R, Solomon G, Neimann AL, Blank RB, Izmirly P, Webster DE, Ogdie A, Troxel AB, Adhikari S, Scher JU; NYU WARCOV Investigators. COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes. Arthritis Rheumatol 2020;72:1981-9. [PMID: 32725762 DOI: 10.1002/art.41456] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 18.5] [Reference Citation Analysis]
27 Haberman RH, Jaros BD, Scher JU. Editorial: Rheumatology at the center of coronavirus disease 2019: pathogenesis, treatment, and clinical care. Curr Opin Rheumatol 2021;33:409-11. [PMID: 34175865 DOI: 10.1097/BOR.0000000000000813] [Reference Citation Analysis]
28 Conway R, Konig MF, Graef ER, Webb K, Yazdany J, Kim AHJ. Inflammatory arthritis in patients with COVID-19. Transl Res 2021;232:49-59. [PMID: 33626415 DOI: 10.1016/j.trsl.2021.02.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Spini A, Giudice V, Brancaleone V, Morgese MG, De Francia S, Filippelli A, Ruggieri A, Ziche M, Ortona E, Cignarella A, Trabace L. Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity. Pharmacol Res 2021;173:105848. [PMID: 34454035 DOI: 10.1016/j.phrs.2021.105848] [Reference Citation Analysis]
30 Byravan S, Fardanesh A, Tahir H, Moorthy A. Emerging COVID-19 vaccines: A rheumatology perspective. Int J Rheum Dis 2021;24:144-6. [PMID: 33523564 DOI: 10.1111/1756-185X.14048] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 D'Silva KM, Jorge A, Cohen A, McCormick N, Zhang Y, Wallace ZS, Choi HK. COVID-19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study. Arthritis Rheumatol 2021;73:914-20. [PMID: 33305544 DOI: 10.1002/art.41619] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 19.0] [Reference Citation Analysis]
32 Huzum B, Curpan AS, Puha B, Serban DN, Veliceasa B, Necoara RM, Alexa O, Serban IL. Connections between Orthopedic Conditions and Oxidative Stress: Current Perspective and the Possible Relevance of Other Factors, Such as Metabolic Implications, Antibiotic Resistance, and COVID-19. Medicina 2022;58:439. [DOI: 10.3390/medicina58030439] [Reference Citation Analysis]
33 Leipe J, Hoyer BF, Iking-Konert C, Schulze-Koops H, Specker C, Krüger K. [SARS-CoV-2 & rheumatic disease : Consequences of the SARS-CoV-2 pandemic for patients with inflammatory rheumatic diseases. A comparison of the recommendations for action of rheumatological societies and risk assessment of different antirheumatic treatments]. Z Rheumatol 2020;79:686-91. [PMID: 32845393 DOI: 10.1007/s00393-020-00878-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
34 Pugliesi A, Sachetto Z, de Medeiros Pinheiro M, Salviato Pileggi G, Sarot Pereira da Cunha G, Hajar FN, Marques Negrisolli Cunha ML, Henrique da Mota LM, Lopes Marques CD, Kakehasi AM, Rodrigues Ferreira WH, Araújo NC, Monteiro Gomides Reis AP, Rodrigues de Abreu Vieira RM, Ferreira GA, Danowski A, de Souza VA, Soares Egypto de Brito DC, Dos Santos Paiva E, Provenza JR, Feijó Azevedo V. How Did Patients Living With Immune-Mediated Rheumatic Diseases Face the Beginning of the COVID-19 Pandemic in Brazil? Results of the COnVIDa Study. J Clin Rheumatol 2022. [PMID: 35699528 DOI: 10.1097/RHU.0000000000001882] [Reference Citation Analysis]
35 Lakota K, Perdan-Pirkmajer K, Hočevar A, Sodin-Semrl S, Rotar Ž, Čučnik S, Žigon P. COVID-19 in Association With Development, Course, and Treatment of Systemic Autoimmune Rheumatic Diseases. Front Immunol 2020;11:611318. [PMID: 33574819 DOI: 10.3389/fimmu.2020.611318] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
36 Bower H, Frisell T, Di Giuseppe D, Delcoigne B, Ahlenius GM, Baecklund E, Chatzidionysiou K, Feltelius N, Forsblad-d'Elia H, Kastbom A, Klareskog L, Lindqvist E, Lindström U, Turesson C, Sjöwall C, Askling J; ARTIS Study Group. Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. Ann Rheum Dis 2021:annrheumdis-2021-219845. [PMID: 33622688 DOI: 10.1136/annrheumdis-2021-219845] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
37 Gamboa-Cárdenas RV, Barzola-Cerrón S, Toledo-Neira D, Reátegui-Sokolova C, Pimentel-Quiroz V, Zevallos-Miranda F, Alarcón GS, Ugarte-Gil M. Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up. Clin Rheumatol 2021. [PMID: 34189675 DOI: 10.1007/s10067-021-05833-1] [Reference Citation Analysis]
38 Fatone MC. COVID-19: A Great Mime or a Trigger Event of Autoimmune Manifestations? Curr Rheumatol Rev 2021;17:7-16. [PMID: 33019935 DOI: 10.2174/1573397116666201005122603] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Jovani V, Calabuig I, Peral-Garrido ML, Tovar-Sugrañes E, López-González MD, Bernabeu P, Martínez A, Esteve-Vives J, León-Ramírez JM, Moreno-Perez O, Boix V, Gil J, Merino E, Vela P, Andrés M. Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors. Ann Rheum Dis 2020:annrheumdis-2020-218152. [PMID: 32586922 DOI: 10.1136/annrheumdis-2020-218152] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
40 Duron G, Gelman L, Dua A, Putman M. Tracking clinical resources for coronavirus disease 2019. Curr Opin Rheumatol 2020;32:441-8. [PMID: 32675716 DOI: 10.1097/BOR.0000000000000724] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
41 Siegel CH, Choi JM, D'Angelo D, Christos P, Lally L, Navarro-Millan I, Cooke J, Goyal P, Mandl LA, Barbhaiya M. Outcomes of COVID-19 and Factors Associated With Its Severity Among Hospitalized Patients With and Without Systemic Rheumatic Disease During the First Wave of the Pandemic in New York City. J Clin Rheumatol 2022. [PMID: 35905465 DOI: 10.1097/RHU.0000000000001891] [Reference Citation Analysis]
42 Ungaro RC, Agrawal M, Park S, Hirten R, Colombel JF, Twyman K, Gulko PS, Klang E. Autoimmune and Chronic Inflammatory Disease Patients with COVID-19. ACR Open Rheumatol 2021;3:111-5. [PMID: 33527691 DOI: 10.1002/acr2.11221] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
43 Ramirez GA, Moroni L, Della-Torre E, Gerosa M, Beretta L, Bozzolo EP, Dagna L. Systemic lupus erythematosus and COVID-19: what we know so far. Ann Rheum Dis 2020:annrheumdis-2020-218601. [PMID: 32859611 DOI: 10.1136/annrheumdis-2020-218601] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
44 Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, Labrique A, Mohan D. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. PLoS One 2021;16:e0247461. [PMID: 33661992 DOI: 10.1371/journal.pone.0247461] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 35.0] [Reference Citation Analysis]
45 Fernandez-Ruiz R, Paredes JL, Niewold TB. COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. Transl Res 2021;232:13-36. [PMID: 33352298 DOI: 10.1016/j.trsl.2020.12.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
46 Yazdany J. COVID-19 in Rheumatic Diseases: A Research Agenda. Arthritis Rheumatol 2020;72:1596-9. [PMID: 32705748 DOI: 10.1002/art.41447] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
47 Marques C, Pinheiro MM, Reis Neto ET, Dantas AT, Ribeiro FM, Melo AKG. COVID-19 in patients with rheumatic diseases: what is the real mortality risk? Ann Rheum Dis 2020:annrheumdis-2020-218388. [PMID: 32660978 DOI: 10.1136/annrheumdis-2020-218388] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
48 Marques CDL, Kakehasi AM, Pinheiro MM, Mota LMH, Albuquerque CP, Silva CR, Santos GPJ, Reis-Neto ET, Matos P, Devide G, Dantas A, Giorgi RD, Marinho AO, Valadares LDA, Melo AKG, Ribeiro FM, Ferreira GA, Santos FPS, Ribeiro SLE, Andrade NPB, Yazbek MA, Souza VA, Paiva ES, Azevedo VF, Freitas ABSB, Provenza JR, Toledo RA, Fontenelle S, Carneiro S, Xavier R, Pileggi GCS, Reis APMG. High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry. RMD Open 2021;7:e001461. [PMID: 33510041 DOI: 10.1136/rmdopen-2020-001461] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
49 Murtas R, Andreano A, Gervasi F, Guido D, Consolazio D, Tunesi S, Andreoni L, Greco MT, Gattoni ME, Sandrini M, Riussi A, Russo AG. Association between autoimmune diseases and COVID-19 as assessed in both a test-negative case-control and population case-control design. Auto Immun Highlights 2020;11:15. [PMID: 33023649 DOI: 10.1186/s13317-020-00141-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
50 Mena-Vázquez N, Manrique Arija S, Rojas-Giménez M, Raya-Álvarez E, Velloso-Feijoó ML, López-Medina C, Ramos-Giraldez C, Godoy-Navarrete FJ, Redondo-Rodríguez R, Cabezas-Lucena AM, Morales-Águila M, Romero-Barco CM, Fernández-Nebro A. Hospitalization and Mortality from COVID-19 of Patients with Rheumatic Inflammatory Diseases in Andalusia. Reumatol Clin (Engl Ed) 2021:S1699-258X(21)00089-9. [PMID: 33895100 DOI: 10.1016/j.reuma.2021.02.009] [Reference Citation Analysis]
51 Gianfrancesco M, Yazdany J, Robinson PC. Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases. Curr Opin Rheumatol 2020;32:434-40. [PMID: 32675715 DOI: 10.1097/BOR.0000000000000725] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
52 Jung Y, Kwon M, Choi HG. Association between previous rheumatoid arthritis and COVID-19 and its severity: a nationwide cohort study in South Korea. BMJ Open 2021;11:e054753. [PMID: 34620675 DOI: 10.1136/bmjopen-2021-054753] [Reference Citation Analysis]
53 Álvaro Gracia JM, Sanchez-Piedra C, Manero J, Ruiz-Lucea ME, López-Vives L, Bohorquez C, Martinez-Barrio J, Bonilla G, Vela P, García-Villanueva MJ, Navío-Marco MT, Pavía M, Galindo M, Erausquin C, Gonzalez-Gay MA, Rua-Figueroa I, Pego-Reigosa JM, Castrejon I, Sanchez-Costa JT, González-Dávila E, Diaz-Gonzalez F; COVIDSER study group. Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study. RMD Open 2021;7:e001925. [PMID: 34887346 DOI: 10.1136/rmdopen-2021-001925] [Reference Citation Analysis]
54 Waldman M, Soler MJ, García-Carro C, Lightstone L, Turner-Stokes T, Griffith M, Torras J, Valenzuela LM, Bestard O, Geddes C, Flossmann O, Budge KL, Cantarelli C, Fiaccadori E, Delsante M, Morales E, Gutierrez E, Niño-Cruz JA, Martinez-Rueda AJ, Comai G, Bini C, La Manna G, Slon MF, Manrique J, Agraz I, Sinaii N, Cravedi P. Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring. Kidney Int 2021;99:227-37. [PMID: 33181156 DOI: 10.1016/j.kint.2020.10.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
55 Patel NJ, D'Silva KM, Hsu TY, DiIorio M, Fu X, Cook C, Prisco L, Martin L, Vanni KMM, Zaccardelli A, Zhang Y, Sparks JA, Wallace ZS. COVID-19 Outcomes Among Users of CD20 Inhibitors for Immune-Mediated Diseases: A Comparative Cohort Study. medRxiv 2021:2021. [PMID: 34401883 DOI: 10.1101/2021.08.05.21261643] [Reference Citation Analysis]
56 Xiao F, Han M, Zhu X, Tang Y, Huang E, Zou H, Jiang Q, Lu L. The immune dysregulations in COVID-19: Implications for the management of rheumatic diseases. Mod Rheumatol 2021;31:927-32. [PMID: 33427554 DOI: 10.1080/14397595.2020.1868673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Xiao F, Wu L, Zhu X, Zhang L, Liu D, Wu L, Zou H, Lu L. Interleukin-6 blocking therapy for COVID-19: From immune pathogenesis to clinical outcomes. Rheumatol Immunol Res 2022;3:11-6. [PMID: 35772080 DOI: 10.2478/rir-2022-0002] [Reference Citation Analysis]
58 Thanou A, Sawalha AH. SARS-CoV-2 and Systemic Lupus Erythematosus. Curr Rheumatol Rep 2021;23:8. [PMID: 33511495 DOI: 10.1007/s11926-020-00973-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
59 Sekar V Dr, Ramasamy G Dr, Ravikumar C. In silico Molecular Docking for assessing Anti-fungal Competency of Hydroxychavicol, a Phenolic Compound of Betel Leaf (Piper betle L.) against COVID-19 Associated Maiming Mycotic Infections. Drug Dev Ind Pharm 2022;:1-43. [PMID: 35311433 DOI: 10.1080/03639045.2022.2048665] [Reference Citation Analysis]
60 Egeli BH, Sparks JA, Kim AHJ, Liew JW. Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain? Best Pract Res Clin Rheumatol 2021;35:101658. [PMID: 33483287 DOI: 10.1016/j.berh.2020.101658] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
61 Eviatar T, Elalouf O, Furer V, Goldstein-Lahat Y, Paran Y, Pel S, Nevo S, Zisapel M, Alcalay Y, Elkayam O. Prevalence of COVID-19 and seroprevalence to SARS-CoV-2 in a rheumatologic patient population from a tertiary referral clinic in Israel. Intern Med J 2021;51:682-90. [PMID: 33844415 DOI: 10.1111/imj.15202] [Reference Citation Analysis]
62 Elemam NM, Maghazachi AA, Hannawi S. COVID-19 infection and rheumatoid arthritis: mutual outburst cytokines and remedies. Curr Med Res Opin 2021;37:929-38. [PMID: 33754931 DOI: 10.1080/03007995.2021.1906637] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Montero F, Martínez-Barrio J, Serrano-Benavente B, González T, Rivera J, Molina Collada J, Castrejón I, Álvaro-Gracia J. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int 2020;40:1593-8. [PMID: 32794113 DOI: 10.1007/s00296-020-04676-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
64 Di Iorio M, Cook CE, Vanni KM, Patel NJ, D'silva KM, Fu X, Wang J, Prisco LC, Kowalski E, Zaccardelli A, Martin LW, Qian G, Hsu TY, Wallace ZS, Sparks JA. DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study. Seminars in Arthritis and Rheumatism 2022;55:152025. [DOI: 10.1016/j.semarthrit.2022.152025] [Reference Citation Analysis]
65 Hasseli R, Mueller-Ladner U, Hoyer BF, Krause A, Lorenz HM, Pfeil A, Richter J, Schäfer M, Schmeiser T, Strangfeld A, Schulze-Koops H, Voll RE, Specker C, Regierer AC. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open 2021;7:e001464. [PMID: 33479021 DOI: 10.1136/rmdopen-2020-001464] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
66 D'Silva KM, Wallace ZS. COVID-19 and Disease-Modifying Anti-rheumatic Drugs. Curr Rheumatol Rep 2021;23:28. [PMID: 33893890 DOI: 10.1007/s11926-021-00998-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
67 Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S, Pertuiset E, Pham T, Marotte H, Servettaz A, Domont F, Chazerain P, Devaux M, Claudepierre P, Langlois V, Mekinian A, Maria ATJ, Banneville B, Fautrel B, Pouchot J, Thomas T, Flipo RM, Richez C; FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors., FAIR/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol 2021;3:e419-26. [PMID: 33786454 DOI: 10.1016/S2665-9913(21)00059-X] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 29.0] [Reference Citation Analysis]
68 Wingert A, Pillay J, Gates M, Guitard S, Rahman S, Beck A, Vandermeer B, Hartling L. Risk factors for severity of COVID-19: a rapid review to inform vaccine prioritisation in Canada. BMJ Open 2021;11:e044684. [PMID: 33986052 DOI: 10.1136/bmjopen-2020-044684] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
69 So H, Mok CC, Yip RML. The Hong Kong Society of Rheumatology Consensus Recommendations for COVID-19 Vaccination in Adult Patients with Autoimmune Rheumatic Diseases. Journal of Clinical Rheumatology and Immunology 2021;21:7-14. [DOI: 10.1142/s2661341721400010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
70 Kridin K, Schonmann Y, Weinstein O, Schmidt E, Ludwig RJ, Cohen AD. The risk of COVID-19 in patients with bullous pemphigoid and pemphigus: A population-based cohort study. J Am Acad Dermatol 2021;85:79-87. [PMID: 33744354 DOI: 10.1016/j.jaad.2021.02.087] [Reference Citation Analysis]
71 Guchelaar NAD, van Laar JAM, Hermans MAW, van der Houwen TB, Atmaca S, van Maaren MS, Brkic Z, van Daele PLA, Dalm VASH, van Hagen PM, Rombach SM. Characteristics of COVID-19 infection and antibody formation in patients known at a tertiary immunology department. J Transl Autoimmun 2021;4:100084. [PMID: 33532723 DOI: 10.1016/j.jtauto.2021.100084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
72 Xu C, Yi Z, Cai R, Chen R, Thong BY, Mu R. Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data. Autoimmun Rev 2021;20:102778. [PMID: 33609804 DOI: 10.1016/j.autrev.2021.102778] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
73 Sözeri B, Demir F, Kalın S, Hasbal Akkuş C, Salı E, Çakır D. SARS-CoV-2 infection in children with rheumatic disease: Experience of a tertiary referral center. Arch Rheumatol 2021;36:381-8. [PMID: 34870170 DOI: 10.46497/ArchRheumatol.2021.8603] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Di Iorio M, Cook CE, Vanni KMM, Patel NJ, D'Silva KM, Fu X, Wang J, Prisco LC, Kowalski E, Zaccardelli A, Martin LW, Qian G, Hsu TY, Wallace ZS, Sparks JA. DMARD disruption, disease flare, and prolonged symptom duration after acute COVID-19 among participants with rheumatic disease: A prospective study. medRxiv 2022:2022. [PMID: 35169813 DOI: 10.1101/2022.02.08.22270696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
75 Fernandez-Ruiz R, Masson M, Kim MY, Myers B, Haberman RH, Castillo R, Scher JU, Guttmann A, Carlucci PM, Deonaraine KK, Golpanian M, Robins K, Chang M, Belmont HM, Buyon JP, Blazer AD, Saxena A, Izmirly PM; NYU WARCOV Investigators. Leveraging the United States Epicenter to Provide Insights on COVID-19 in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol 2020;72:1971-80. [PMID: 32715660 DOI: 10.1002/art.41450] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 13.0] [Reference Citation Analysis]
76 Gianfrancesco M, Hyrich KL, Yazdany J, Machado PM, Robinson PC. COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a real-world district general hospital experience' by Khan et al, 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M et al' by Andreica et al and 'COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs' by Ansarin et al. Ann Rheum Dis 2020:annrheumdis-2020-218713. [PMID: 32796043 DOI: 10.1136/annrheumdis-2020-218713] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
77 Miller DC, Sun Y, Chen EM, Arnold BF, Acharya NR. The Association between Noninfectious Uveitis and Coronavirus Disease 2019 Outcomes: An Analysis of United States Claims-Based Data. Ophthalmology 2021:S0161-6420(21)00751-X. [PMID: 34648828 DOI: 10.1016/j.ophtha.2021.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
78 Sakthiswary R, Chuah HY, Chiang KS, Liew YS, Muhammad Aizat NA. COVID-19 in systemic lupus erythematosus: A pooled analysis and systematic review of case reports and series. Lupus 2021;30:1946-54. [PMID: 34565208 DOI: 10.1177/09612033211045057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Shah SB. COVID-19 and Progesterone: Part 2. Unraveling High Severity, Immunity Patterns, Immunity grading, Progesterone and its potential clinical use. Endocr Metab Sci 2021;:100110. [PMID: 34396354 DOI: 10.1016/j.endmts.2021.100110] [Reference Citation Analysis]
80 Loarce-Martos J, García-Fernández A, López-Gutiérrez F, García-García V, Calvo-Sanz L, Del Bosque-Granero I, Terán-Tinedo MA, Boteanu A, Bachiller-Corral J, Vázquez-Díaz M. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int 2020;40:2015-21. [PMID: 32945944 DOI: 10.1007/s00296-020-04699-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 16.0] [Reference Citation Analysis]
81 Arleo T, Tong D, Shabto J, O'Keefe G, Khosroshahi A. Clinical course and outcomes of COVID-19 in rheumatic disease patients: a case cohort study with a diverse population. Clin Rheumatol 2021;40:2633-42. [PMID: 33420870 DOI: 10.1007/s10067-021-05578-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
82 Cordtz R, Lindhardsen J, Soussi BG, Vela J, Uhrenholt L, Westermann R, Kristensen S, Nielsen H, Torp-Pedersen C, Dreyer L. Incidence and severeness of COVID-19 hospitalisation in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark. Rheumatology (Oxford) 2020:keaa897. [PMID: 33369663 DOI: 10.1093/rheumatology/keaa897] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
83 Mageau A, Papo T, Ruckly S, Strukov A, van Gysel D, Sacre K, Timsit JF. Survival after COVID-19-associated organ failure among inpatients with systemic lupus erythematosus in France: a nationwide study. Ann Rheum Dis 2021:annrheumdis-2021-221599. [PMID: 34893471 DOI: 10.1136/annrheumdis-2021-221599] [Reference Citation Analysis]
84 Furer V, Rondaan C, Agmon-Levin N, van Assen S, Bijl M, Kapetanovic MC, de Thurah A, Mueller-Ladner U, Paran D, Schreiber K, Warnatz K, Wulffraat NM, Elkayam O. Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases. RMD Open 2021;7:e001594. [PMID: 33627440 DOI: 10.1136/rmdopen-2021-001594] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
85 Raza HA, Tariq J, Agarwal V, Gupta L. COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases. Rheumatol Int 2021;41:257-73. [PMID: 33386447 DOI: 10.1007/s00296-020-04759-2] [Reference Citation Analysis]
86 Tang X, Geng L, Feng X, Sun L. Decreased serum ACE2 levels in patients with connective tissue diseases. Rheumatology 2021;60:4401-6. [DOI: 10.1093/rheumatology/keaa898] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
87 Ahmed S, Gasparyan AY, Zimba O. Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic. Rheumatol Int 2021;41:243-56. [PMID: 33388969 DOI: 10.1007/s00296-020-04764-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
88 Grainger R, Machado PM, Robinson PC. Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes. Best Pract Res Clin Rheumatol 2021;35:101657. [PMID: 33468418 DOI: 10.1016/j.berh.2020.101657] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
89 Kilian A, Chock YP, Huang IJ, Graef ER, Upton LA, Khilnani A, Krupnikova SDS, Almaghlouth I, Cappelli LC, Fernandez-Ruiz R, Frankel BA, Frankovich J, Harrison C, Kumar B, Monga K, Vega JAR, Singh N, Sparks JA, Sullo E, Young KJ, Duarte-Garcia A, Putman M, Johnson S, Grainger R, Wallace ZS, Liew JW, Jayatilleke A. Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. Semin Arthritis Rheum 2020;50:1191-201. [PMID: 32931985 DOI: 10.1016/j.semarthrit.2020.07.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
90 Pablos JL, Galindo M, Carmona L, Lledó A, Retuerto M, Blanco R, Gonzalez-Gay MA, Martinez-Lopez D, Castrejón I, Alvaro-Gracia JM, Fernández Fernández D, Mera-Varela A, Manrique-Arija S, Mena Vázquez N, Fernandez-Nebro A; RIER Investigators Group., RIER investigators group. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis 2020;79:1544-9. [PMID: 32796045 DOI: 10.1136/annrheumdis-2020-218296] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 23.5] [Reference Citation Analysis]
91 Shin YH, Shin JI, Moon SY, Jin HY, Kim SY, Yang JM, Cho SH, Kim S, Lee M, Park Y, Kim MS, Won HH, Hong SH, Kronbichler A, Koyanagi A, Jacob L, Smith L, Lee KH, Suh DI, Lee SW, Yon DK. Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study. Lancet Rheumatol 2021. [PMID: 34179832 DOI: 10.1016/S2665-9913(21)00151-X] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
92 Schulze-Koops H, Krüger K, Hoyer BF, Leipe J, Iking-Konert C, Specker C; Commission for Pharmacotherapy and the Board of Directors of the German Society for Rheumatology. Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in times of SARS-CoV-2-methodology, key messages and justifying information. Rheumatology (Oxford) 2021;60:2128-33. [PMID: 33502500 DOI: 10.1093/rheumatology/keab072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
93 Koppe U, Wilking H, Harder T, Haas W, Rexroth U, Hamouda O. [COVID-19 patients in Germany: exposure risks and associated factors for hospitalization and severe disease]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2021;64:1107-15. [PMID: 34327540 DOI: 10.1007/s00103-021-03391-0] [Reference Citation Analysis]
94 Favalli EG, Maioli G, Biggioggero M, Caporali R. Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic. Expert Rev Clin Immunol 2021;17:561-71. [PMID: 33787418 DOI: 10.1080/1744666X.2021.1908887] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Sarmiento-Monroy JC, Espinosa G, Londoño MC, Meira F, Caballol B, Llufriu S, Carrasco JL, Moll-Udina A, Quintana LF, Giavedoni P, Ramírez J, Inciarte-Mundo J, Solana E, Blanco Y, Martinez-Hernandez E, Sepúlveda M, Llorenç V, Prieto-González S, Espígol-Frigolé G, Milisenda JC, Cid MC, Mascaró JM Jr, Blanco I, Barberá JA, Sibila O, Gratacos-Ginès J, Adán A, Agustí A, Sanmartí R, Panés J, Cervera R, Vila J, Soriano A, Gómez-Puerta JA; Immunocovid Clinic. A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. J Autoimmun 2021;117:102580. [PMID: 33338707 DOI: 10.1016/j.jaut.2020.102580] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
96 Zhong J, Ye C, Cai S, Dong L. Response to: 'Comment on Ye et al 'Presence of respiratory failure of COVID-19 infection in patients with rheumatism in Wuhan, China'' by Chen et al. Ann Rheum Dis 2020:annrheumdis-2020-218508. [PMID: 32709681 DOI: 10.1136/annrheumdis-2020-218508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
97 Patel NJ, D'Silva KM, Hsu TY, DiIorio M, Fu X, Cook C, Prisco L, Martin L, Vanni KMM, Zaccardelli A, Zhang Y, Sparks JA, Wallace ZS. Coronavirus Disease 2019 Outcomes Among Recipients of Anti-CD20 Monoclonal Antibodies for Immune-Mediated Diseases: A Comparative Cohort Study. ACR Open Rheumatol 2021. [PMID: 34890478 DOI: 10.1002/acr2.11386] [Reference Citation Analysis]
98 Alyammahi SK, Abdin SM, Alhamad DW, Elgendy SM, Altell AT, Omar HA. The dynamic association between COVID-19 and chronic disorders: An updated insight into prevalence, mechanisms and therapeutic modalities. Infect Genet Evol 2021;87:104647. [PMID: 33264669 DOI: 10.1016/j.meegid.2020.104647] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
99 Shahram F, Esalatmanesh K, Khabbazi A, Rezaieyazdi Z, Mirfeizi Z, Sadeghi A, Soroosh M, Kavosi H, Alikhani M, Mostafaei S. Coronavirus disease 2019 in patients with Behcet's disease: a report of 59 cases in Iran. Clin Rheumatol 2021. [PMID: 34842999 DOI: 10.1007/s10067-021-06004-y] [Reference Citation Analysis]
100 Abutiban F, Saleh K, Hayat S, Tarakmah H, Al-Herz A, Ghanem A. COVID-19 outcomes among rheumatic disease patients in Kuwait: Data from the COVID-19 Global Rheumatology Alliance (C19-GRA) physician registry. Int J Rheum Dis 2022. [PMID: 35543332 DOI: 10.1111/1756-185X.14332] [Reference Citation Analysis]
101 D'Silva KM, Wallace ZS. COVID-19 and rheumatoid arthritis. Curr Opin Rheumatol 2021;33:255-61. [PMID: 33625043 DOI: 10.1097/BOR.0000000000000786] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
102 [DOI: 10.1101/2020.12.21.20248610] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
103 Treskova-Schwarzbach M, Haas L, Reda S, Pilic A, Borodova A, Karimi K, Koch J, Nygren T, Scholz S, Schönfeld V, Vygen-Bonnet S, Wichmann O, Harder T. Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence. BMC Med 2021;19:212. [PMID: 34446016 DOI: 10.1186/s12916-021-02058-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
104 Kawano Y, Patel NJ, Wang X, Cook CE, Vanni KMM, Kowalski EN, Banasiak EP, Qian G, DiIorio M, Hsu TYT, Weinblatt ME, Todd DJ, Wallace ZS, Sparks JA. Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: From the first wave to Omicron. medRxiv 2022:2022. [PMID: 35765565 DOI: 10.1101/2022.06.19.22276599] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
105 Sengler C, Eulert S, Minden K, Niewerth M, Horneff G, Kuemmerle-Deschner J, Siemer C, Berendes R, Girschick H, Hühn R, Borte M, Hospach A, Emminger W, Armann J, Klein A, Kallinich T. Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany. RMD Open 2021;7:e001687. [PMID: 34312307 DOI: 10.1136/rmdopen-2021-001687] [Reference Citation Analysis]
106 Jorge A, D'Silva KM, Cohen A, Wallace ZS, McCormick N, Zhang Y, Choi HK. Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study. Lancet Rheumatol 2021;3:e131-7. [PMID: 33392516 DOI: 10.1016/S2665-9913(20)30422-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
107 Robinson PC, Bursle EC; Senior staff specialist2., Infectious diseases physician3., Clinical microbiologist34. Management of autoimmune disease during the COVID-19 pandemic. Aust Prescr 2020;43:146-7. [PMID: 33093739 DOI: 10.18773/austprescr.2020.058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
108 Sparks JA, Wallace ZS, Robinson PC. Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease. Curr Opin Rheumatol 2021;33:412-8. [PMID: 34171857 DOI: 10.1097/BOR.0000000000000812] [Reference Citation Analysis]
109 Lucio Liberato N, De Monte A, Caravella G. Tocilizumab in severe COVID-19. Arch Med Sci 2020;16:1457-8. [PMID: 33224347 DOI: 10.5114/aoms.2020.97411] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
110 Ayala Gutiérrez MDM, Rubio-Rivas M, Romero Gómez C, Montero Sáez A, Pérez de Pedro I, Homs N, Ayuso García B, Cuenca Carvajal C, Arnalich Fernández F, Beato Pérez JL, Vargas Núñez JA, Letona Giménez L, Suárez Fernández C, Méndez Bailón M, Tuñón de Almeida C, González Moraleja J, de Guzmán García-Monge M, Helguera Amezua C, Fidalgo Montero MDP, Giner Galvañ V, Gil Sánchez R, Collado Sáenz J, Boixeda R, Ramos Rincón JM, Gómez Huelgas R, On Behalf Of The Semi-Covid-Network. Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry. J Clin Med 2021;10:1844. [PMID: 33922777 DOI: 10.3390/jcm10091844] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Robinson PC, Yazdany J, Machado PM. Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance. Curr Opin Rheumatol 2021;33:111-6. [PMID: 33394601 DOI: 10.1097/BOR.0000000000000783] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
112 Walbi IA, Albarqi HA, Alghanim NS, Albadi MA, Al Maimouni HM, Alkahtani SA, Alshabi AM, Alali AS, Alqahtani F, Al-Najjar AH, Hazzazi MA, Alanazi DS, Sabei AA, Alsaweed OS, Alajra RK, Alqhtani H. Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort. J Int Med Res 2022;50:3000605221090363. [PMID: 35387504 DOI: 10.1177/03000605221090363] [Reference Citation Analysis]
113 AlBloushi AF, Alfawaz AM, Abu El Asrar AM. Implications of COVID-19 infection on patients with uveitis under biologic treatment. Br J Ophthalmol 2021:bjophthalmol-2020-318577. [PMID: 33931386 DOI: 10.1136/bjophthalmol-2020-318577] [Reference Citation Analysis]
114 Ziadé N, Hmamouchi I, El Kibbi L, Abdulateef N, Halabi H, Abutiban F, Hamdi W, El Rakawi M, Eissa M, Masri B. The impact of COVID-19 pandemic on rheumatology practice: a cross-sectional multinational study. Clin Rheumatol 2020;39:3205-13. [PMID: 32996071 DOI: 10.1007/s10067-020-05428-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
115 Goldman JD, Robinson PC, Uldrick TS, Ljungman P. COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. J Immunother Cancer 2021;9:e002630. [PMID: 34117116 DOI: 10.1136/jitc-2021-002630] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
116 Pileggi GS, Ferreira GA, Reis APMG, Reis-Neto ET, Abreu MM, Albuquerque CP, Araújo NC, Bacchiega AB, Bianchi DV, Bica B, Bonfa ED, Borba EF, Brito DCSE, Duarte ÂLBP, Santo RCE, Fernandes PR, Guimarães MP, Gomes KWP, Kakehasi AM, Klumb EM, Lanna CCD, Marques CDL, Monticielo OA, Mota LMH, Munhoz GA, Paiva ES, Pereira HLA, Provenza JR, Ribeiro SLE, Junior LFR, Sampaio CSJC, Sampaio VS, Sato EI, Skare T, de Souza VA, Valim V, Lacerda MVG, Xavier RM, Pinheiro MM. Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil. Adv Rheumatol 2021;61:60. [PMID: 34620246 DOI: 10.1186/s42358-021-00217-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Yang H, Xu J, Liang X, Shi L, Wang Y. Autoimmune diseases are independently associated with COVID-19 severity: Evidence based on adjusted effect estimates. J Infect 2021;82:e23-6. [PMID: 33383087 DOI: 10.1016/j.jinf.2020.12.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]